SS
GYRE icon

SBI Securities’s Gyre Therapeutics GYRE Stock Holding History

SBI Securities’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.1M Sell
166,750
-4,087
-2% -$27.8K 0.03% 272
2026
Q1 		$1.19M Buy
170,837
+7,922
+5% +$61.5K 0.03% 245
2025
Q4 		$1.15M Sell
162,915
-4,951
-3% -$38.2K 0.03% 257
2025
Q3 		$1.25M Sell
167,866
-64,433
-28% -$489K 0.03% 246
2025
Q2 		$1.71M Buy
232,299
+108,670
+88% +$948K 0.05% 198
2025
Q1 		$954K Buy
123,629
+22,390
+22% +$246K 0.03% 254
2024
Q4 		$1.22M Buy
+101,239
New +$1.3M 0.04% 227

Other funds holding GYRE

HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SBI Securities's GYRE Position: Q2 2026 in Review

SBI Securities reduced its Gyre Therapeutics (GYRE) stake by 2.4% in Q2 2026, selling an estimated $27.8K and leaving 166,750 shares worth $1.1M. The position accounts for 0.03% of the portfolio, ranked #272.

SBI Securities first reported a position in GYRE in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.71M in Q2 2025. 60 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

  • SBI Securities held 166,750 shares of Gyre Therapeutics worth $1.1M as of Q2 2026.
  • SBI Securities sold 4,087 Gyre Therapeutics shares in Q2 2026, an estimated $27.8K.
  • Gyre Therapeutics made up 0.03% of SBI Securities's portfolio in Q2 2026, its #272 holding.
  • SBI Securities first reported a position in Gyre Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Gyre Therapeutics position peaked at $1.71M in Q2 2025.
  • 60 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.